C

Cardiff Oncology
D

CRDF

4.14000
USD
0.34
(8.80%)
مفتوح الان
حجم التداول
34,374
الربح لكل سهم
0
العائد الربحي
0
P/E
-5
حجم السوق
193,180,981
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    ABT
    4.220
    (3.98%)
    110.150 USD
    AZN
    2.040
    (2.58%)
    81.200 USD
    B
    BNTX
    -5.530
    (-6.42%)
    80.570 USD
    GSK
    0.865
    (2.23%)
    39.650 USD
    JNJ
    2.930
    (1.86%)
    160.770 USD
    MDT
    0.160
    (0.20%)
    80.470 USD
    MRNA
    -25.020
    (-20.99%)
    94.160 USD
    N
    NVAX
    -0.250
    (-1.95%)
    12.560 USD
    PFE
    0.115
    (0.38%)
    30.650 USD
    REGN
    13.14
    (1.22%)
    1,091.19 USD
    TMO
    9.03
    (1.47%)
    621.78 USD
    المزيد
الأخبار
المقالات

العنوان: Cardiff Oncology

القطاع: Healthcare
الصناعة: Biotechnology
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").